Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

NCT02845297 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

67

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: pembrolizumab
DRUG: Azacitadine

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]